Freenome, a privately held biotech company, announced the completion of enrollment for PREEMPT CRC, the company’s large, prospective study to validate its blood test for colorectal cancer (CRC) screening among average-risk adults.
The test uses Freenome’s multiomics platform, which combines both tumor and non-tumor signals with machine learning to detect cancer in the earliest, most treatable stages using a standard blood draw. PREEMPT CRC builds on data demonstrating a sensitivity of 94% and a specificity of 94% for detecting early-stage (I/II) CRC, and additional data highlighting the significance of detecting adenomas.